GlassScriptPhysician profile
Nikesh Ramesh Jasani
NPI 1215096912
$9,729.27
in general payments reported to CMS, 2019-2025
60 companies · $2,545 in 2025
The $2,545 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $43.80 · 2021: $152 · 2022: $1,280 · 2023: $2,348 · 2024: $3,137 · 2025: $2,545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,308 · Long Term Medical Supply Or Device Loan: $1,579 · Education: $143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,307.94 |
| Long Term Medical Supply Or Device Loan | $1,578.83 |
| Education | $142.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,269.13 | 2022-2025 | |
| Celgene Corporation | $546.63 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Pfizer INC. | $503.05 | 2022-2025 | |
| Janssen Biotech, INC. | $423.85 | 2022-2025 | Rybrevant, Tecvayli, Erleada |
| Myriad Genetic Laboratories, INC. | $401.95 | 2021-2024 | Myrisk |
| Astrazeneca Pharmaceuticals LP | $361.75 | 2019-2025 | Enhertu, Lynparza, Calquence |
| E.R. Squibb & Sons, L.L.C. | $330.72 | 2021-2025 | Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $269.38 | 2024-2025 | |
| Sobi, INC | $267.77 | 2023-2025 | |
| Daiichi Sankyo INC. | $257.90 | 2020-2025 | Enhertu, Datroway |
| Astellas Pharma US INC | $257.19 | 2022-2025 | Padcev, Vyloy, Xtandi |
| Gilead Sciences, INC. | $245.80 | 2021-2025 | Trodelvy |
| Tersera Therapeutics LLC | $220.57 | 2023-2025 | Zoladex, Xermelo, Quzyttir |
| Glaxosmithkline, LLC. | $209.21 | 2022-2025 | Ojjaara, Blenrep, Jemperli |
| Genzyme Corporation | $204.35 | 2022-2025 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $181.75 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $174.16 | 2022-2023 | Kyprolis, Blincyto, Nplate |
| Adaptive Biotechnologies Corporation | $160.77 | 2022-2025 | Clonoseq |
| Tempus Ai, INC | $148.41 | 2024-2025 | Xt Cdx |
| Eisai INC. | $146.99 | 2023-2025 | |
| Lilly USA, LLC | $138.79 | 2019-2022 | |
| Springworks Therapeutics, INC. | $127.30 | 2024-2025 | Ogsiveo, Gomekli |
| Array Biopharma INC | $116.10 | 2022-2025 | Lorbrena, Braftovi, Mektovi |
| Puma Biotechnology, INC. | $110.85 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $109.32 | 2022-2024 | Rezlidhia, Tavalisse |
| Alexion Pharmaceuticals, INC. | $91.33 | 2022-2023 | Ultomiris |
| Boston Scientific Corporation | $89.04 | 2024-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Watchman Flx |
| Aveo Pharmaceuticals, INC. | $85.12 | 2022-2023 | Fotivda |
| Genentech USA, INC. | $82.28 | 2023-2025 | Venclexta, Lunsumio, Columvi |
| Beigene USA, INC. | $80.23 | 2023-2025 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $77.69 | 2023-2024 | Alunbrig, Hyqvia, Ninlaro |
| Abbvie INC. | $75.54 | 2020-2024 | |
| Taiho Oncology, INC. | $70.91 | 2019-2023 | |
| Cti Biopharma Corp. | $69.07 | 2022-2023 | Vonjo |
| Bayer Healthcare Pharmaceuticals INC. | $59.66 | 2019-2023 | |
| Dendreon Pharmaceuticals LLC | $59.38 | 2024-2025 | Provenge |
| Immunocore Limited | $54.44 | 2024 | Kimmtrak |
| Karyopharm Therapeutics INC. | $53.63 | 2023-2024 | Xpovio |
| Pharmaessentia USA Corporation | $53.27 | 2022 | |
| Deciphera Pharmaceuticals INC. | $49.50 | 2022-2024 | Qinlock |
| Seagen INC. | $35.65 | 2023 | Padcev, Adcetris |
| Kite Pharma, INC. | $33.99 | 2025 | Yescarta |
| Abbott Laboratories | $31.65 | 2019 | |
| Caris Mpi, INC. | $31.26 | 2025 | Mi Cancer Seek |
| Apellis Pharmaceuticals, INC. | $30.87 | 2023 | |
| Sumitomo Pharma America, INC. | $29.53 | 2023 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $28.38 | 2024 | Tazverik |
| Geron Corporation | $27.67 | 2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $25.72 | 2024 | |
| Secura Bio, INC. | $25.34 | 2024 | Copiktra |
| Beone Medicines USA, INC. | $24.62 | 2025 | Brukinsa |
| Stemline Therapeutics INC. | $22.50 | 2025 | Orserdu |
| G1 Therapeutics, INC. | $21.27 | 2023 | Cosela |
| Tolmar Pharmaceuticals, INC. | $20.42 | 2022 | |
| Recordati_rare_diseases_inc. | $20.15 | 2025 | Enjaymo |
| Adc Therapeutics America, INC. | $18.01 | 2025 | |
| Aimmune Therapeutics, INC. | $17.71 | 2025 | Zenpep |
| Incyte Corporation | $17.15 | 2023 | Jakafi |
| Agios Pharmaceuticals, INC. | $16.59 | 2024 | |
| Mirati Therapeutics, INC. | $16.01 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikesh Jasani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.